Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$1.07MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Shaun R. Bagai
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Beta
- 0.97
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -1.69
Financials
Revenue
$1.07M+2379.1%Net Income
$-3.65MEBITDA
$-3.64MFree Cash Flow
$-2.56MEPS (diluted)
$-0.08Shares Outstanding (diluted)
48.19M+310.9%Operating Expenses
$4.11MCash & Debt
$10.40MRevenue by Segment (annual)
$1.12MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.12M | $-11.17M | $-0.32 |
| 2024 | $43.0K | $-8.81M | $-0.37 |
| 2023 | $0.00 | $-10.23M | $-0.50 |
| 2022 | $0.00 | $-9.89M | $-0.54 |
| 2021 | $0.00 | $-6.32M | $-0.40 |
| 2020 | $0.00 | $-3.80M | $-0.25 |
| 2019 | $0.00 | $-3.84M | $-0.22 |
Valuation
RNXThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
37+0.00%Social Signal Score
Mentions (14)
- Newsglobenewswire.com·3d ago·Negative
RenovoRx Appoints Interventional Oncology Medtech Leader Richard Stark to its Board of Directors MOUNTAIN VIEW, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, and evaluating a novel targeted oncology drug-device product candidate, today announced the appointment of Richard A.
View source ↗ - Newsmarketbeat.com·16d ago·Negative
RenovoRx Q3 Earnings Call Highlights RenovoRx NASDAQ: RNXT reported record third-quarter 2026 revenue of $1.07 million, exceeding $1 million in quarterly sales for the first time as more cancer centers adopted its RenovoCath drug-delivery device.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
RenovoRx, Inc. (RNXT) Q3 2026 Earnings Call Transcript RenovoRx, Inc. (RNXT) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·17d ago·Negative
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago.
View source ↗ - Newsglobenewswire.com·25d ago·Negative
…dTech Diagnostics and Digital Health & Services Forum MOUNTAIN VIEW, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, are scheduled to present at the Canaccord Genuity MedTech, Diagnostics an…
View source ↗ - Newsglobenewswire.com·31d ago·Negative
…al Results and Business Highlights on November 5, 2026 MOUNTAIN VIEW, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that it will release third quarter 2026 financial results and business highlights after market close on Thursday, November 5, 2026.
View source ↗ - Newsglobenewswire.com·46d ago·Negative
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial University of Vermont-Sponsored IIT Explores TAMP in a New Clinical Setting: TAMP Utilization Prior to Surgical Resection University of Vermont-Sponsored IIT Explores TAMP in a New Clinical Setting: TAMP Utilization Prior to Surgical Resection
View source ↗ - Newsglobenewswire.com·52d ago·Negative
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer Case Series Reports Tumor Treatment Response, Significant Tumor Marker Reduction, and Changes on Imaging After Treatment with TAMP in Patients with Unresectable LAPC Case Series Reports Tumor Treatment Response, Significant Tumor Marker Reduction, and Changes on Imaging After Treatment with TAMP in Patients with Unresectable LAPC
View source ↗ - Newsglobenewswire.com·89d ago·Negative
…ween Drug Metabolite Levels and Tumor Marker Reduction MOUNTAIN VIEW, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced the publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial (NCT03257033) in the …
View source ↗ - Newsglobenewswire.com·93d ago·Neutral
…s Compliance with Nasdaq Minimum Bid Price Requirement MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that it has received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum b…
View source ↗ - Newsglobenewswire.com·94d ago·Negative
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commercialization of RenovoCath As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellect
View source ↗ - Newsmarketbeat.com·98d ago·Positive
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers RenovoRx NASDAQ: RNXT executives and physician speakers discussed the treatment landscape for locally advanced pancreatic cancer, the company's Trans-Arterial Micro-Perfusion, or TAMP, platform, and commercialization progress for its RenovoCath delivery device during a webinar hosted by JonesTrading.
View source ↗ - Newsmarketbeat.com·102d ago·Neutral
RenovoRx Q2 Earnings Call Highlights RenovoRx NASDAQ: RNXT reported record second-quarter revenue as it expanded its commercial cancer-center network and advanced its clinical program for locally advanced pancreatic cancer.
View source ↗ - Newszacks.com·102d ago·Neutral
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.08 per share a year ago.
View source ↗
Earnings
Mon, Mar 29(in 4 months)
Consensus estimate $-0.07 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.07 vs $-0.06miss
- Wed, Aug 12$-0.05 vs $-0.07beat
- Thu, May 14$-0.08 vs $-0.08beat
- Mon, Mar 30$-0.08 vs $-0.08beat
- Thu, Nov 13$-0.08 vs $-0.08beat
- Thu, Aug 14$-0.08 vs $-0.08beat
Estimates and results for RNXT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RNXT officers and directors.
- Bought
- $837k
- Sold
- —
43 trades
0 trades
- Agah Ramtinbought
- Voll Markbought
- Marton Laurencebought
- Marton Laurencebought
- Bagai Shaunbought
- Bagai Shaunbought
- Voll Markbought
- Voll Markbought
57 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RNXT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
